Gene Editing
Overview
R&D Platforms
Manufacturing
Papers & Presentations
Our Pipeline
Our Pipeline
Ex Vivo
Therapies
In Vivo
Therapies
Our Focus
Genetic Diseases
Cancer
About Us
Company Overview
Scientific Founder
Leadership
Contact Us
Careers
Company Culture
Join Us
News
Press Releases
In the Media
简体中文
中文
Edit Code of Life,
Creating Transformative Solutions for Serious Human Diseases
Press Releases
In the Media
>
News
>
Press Releases
Press Releases
All
2022
2021
2020
2019
2018
Search
23
2021-11
EdiGene Enters Research Collaboration to Develop Gene-editing Therapies for Inherited Retinal Degeneration with Peking Union Medical College Hospital
LEARN MORE
09
2021-11
EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on
In Vivo
RNA Editing Therapies
LEARN MORE
04
2021-11
EdiGene to Present Latest Research on a Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) that could Enhance HSC Gene Therapy and HSC Transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
LEARN MORE
02
2021-11
EdiGene Secures New Lab and Office Space for Its Growing U.S. R&D Center to Advance Gene-editing Based Therapies
LEARN MORE
08
2021-09
EdiGene Announces Clinical Sites Activation and First Patient Enrolled in Multicenter Phase I Clinical Trial of its Investigational Gene-editing Hematopoietic Stem Cell Therapy ET-01 for Patients with Transfusion Dependent β-thalassemia
LEARN MORE
21
2021-04
EdiGene Raises Approximately USD 62 Million in Series B Plus Financing and Expands Operation Locations to Advance and Scale Up Clinical Translation of Gene Editing Technologies
LEARN MORE
18
2021-01
EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia by China National Medical Products Administration
LEARN MORE
14
2020-12
EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan
LEARN MORE
27
2020-10
EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration
LEARN MORE
13
2020-10
EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage
LEARN MORE
1
2
3
4
